Valve and implant compared for refractory glaucoma

Article

Patients with refractory glaucoma in whom a proprietary glaucoma implant was placed needed significantly less adjunctive medication to experience success in treatment compared with those who received a proprietary glaucoma valve. However, fewer of those in the latter group had serious postoperative complications, according to recently published 3-year outcomes.

Patients with refractory glaucoma in whom a proprietary glaucoma implant (Baerveldt, Abbott Medical Optics) was placed needed significantly less adjunctive medication to experience success in treatment compared with those who received a proprietary glaucoma valve (Ahmed FP7, New World Medical). However, fewer of those in the latter group had serious postoperative complications, according to 3-year outcomes reported in a study published online by Ophthalmology.

The multicentre, randomized, controlled clinical trial included 133 participants in the implant group and 143 in the valve group. Participants were aged 18 to 85 years and had IOP ≥18 mmHg. They were randomly assigned to receive the implant or valve.

The main outcomes at 3 years as measured by researchers from the UK, the US and Brazil:

  • IOP. The investigators found that IOP (mean ± standard deviation) was 14.3 ± 4.7 mmHg in the valve group and 13.1 ± 4.5 mmHg in the implant group.
  • VA. The mean change in the logarithm of the minimum angle of resolution VA was similar in both treatment groups.
  • Supplemental medical therapy. Participants were taking 2.0 ± 1.4 glaucoma medications in the valve group and 1.5 ± 1.4 in the implant group.
  • Complications. Postoperative complications associated with reoperation or vision loss of >2 Snellen lines occurred in 24 patients in the valve group and 38 patients in the implant group.
  • Failure (defined as IOP >21 mmHg or not reduced by 20% from baseline, IOP

For more information, you can access the abstract here.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
© 2025 MJH Life Sciences

All rights reserved.